Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
15.00
-0.15 (-0.99%)
At close: Feb 21, 2025, 4:00 PM
14.85
-0.15 (-1.00%)
After-hours: Feb 21, 2025, 6:46 PM EST
Capricor Therapeutics Employees
As of December 31, 2023, Capricor Therapeutics had 102 total employees, including 101 full-time and 1 part-time employees. The number of employees increased by 28 or 37.84% compared to the previous year.
Employees
102
Change (1Y)
28
Growth (1Y)
37.84%
Revenue / Employee
$227,726
Profits / Employee
-$334,438
Market Cap
682.05M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
CAPR News
- 7 weeks ago - Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy - GlobeNewsWire
- 2 months ago - RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead - Market Watch
- 2 months ago - Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached - Seeking Alpha
- 2 months ago - Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission - Seeking Alpha
- 2 months ago - Capricor Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire